• 1
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 16871717.
  • 2
    Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001; 93: 684690.
  • 3
    Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97: 12621271.
  • 4
    GreeneFL, PageDL, FlemingID, et al., editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
  • 5
    Fowble B, Freedman G. Cancer of the breast. In: WangCC, editor. Clinical Radiation Oncology: Indications, Techniques and Results. 2nd ed. New York: Wiley-Liss; 2000.
  • 6
    National Comprehensive Cancer Network. NCCN practice guidelines for breast cancer. 2005. Available at URL: [accessed August 31, 2006].
  • 7
    Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996; 14: 27382746.
  • 8
    Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol. 2000; 18: 27182727.
  • 9
    United States Department of Health and Human Services. Bone Health and Osteoporosis. A Report of the Surgeon General. Washington, DC: Government Printing Office; 2004.